CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001

SUZHOU, China, Sept. 20, 2024 /PRNewswire/ — CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial. CD-001, the company’s leading clinical…